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In this study, we developed the cancer treatment through the combination of chemotherapy and thermotherapy
using doxorubicin-loaded magnetic liposomes. The citric acid-coated magnetic nanoparticles (CAMNP, ca. 10 nm)
and doxorubicin were encapsulated into the liposome (HSPC/DSPE/cholesterol = 12.5:1:8.25) by rotary evaporation
and ultrasonication process. The resultant magnetic liposomes (ca. 90 to 130 nm) were subject to characterization
including transmission electron microscopy (TEM), dynamic light scattering (DLS), X-ray diffraction (XRD), zeta potential,
Fourier transform infrared (FTIR) spectrophotometer, and fluorescence microscope. In vitro cytotoxicity of the drug
carrier platform was investigated through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
using L-929 cells, as the mammalian cell model. In vitro cytotoxicity and hyperthermia (inductive heating) studies were
evaluated against colorectal cancer (CT-26 cells) with high-frequency magnetic field (HFMF) exposure. MTT assay
revealed that these drug carriers exhibited no cytotoxicity against L-929 cells, suggesting excellent biocompatibility.
When the magnetic liposomes with 1 μM doxorubicin was used to treat CT-26 cells in combination with HFMF
exposure, approximately 56% cells were killed and found to be more effective than either hyperthermia or
chemotherapy treatment individually. Therefore, these results show that the synergistic effects between
chemotherapy (drug-controlled release) and hyperthermia increase the capability to kill cancer cells.
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Development of smart materials that could response to
the environmental stimuli is gaining importance over
the past decade in the drug delivery system [1]. Remote
control drug carrier behavior has been regarded as a
function that could enhance the efficacy and efficiency
of drug delivery to the target sites [2,3]. Among several
drug carrier candidates, liposomes exhibit a number of
excellences. Liposomes are synthetic lipid bilayer with
enclosed structure up to several hundred nanometers in
diameter. It is highly biocompatible and biodegradable* Correspondence: myang@mail.ntust.edu.tw; tyliu0322@gmail.com
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reproduction in any medium, provided the origand can encapsulate both hydrophilic and hydrophobic
pharmaceutical agents and protect them from the in-
activating effect of external condition. Moreover, liposomes
provide a unique characteristic to deliver pharmaceuticals
into cells or even inside individual compartments [4-7].
Recently, researchers have developed novel liposomes to
provide a smart treatment in human body which can
undergo the releasing of encapsulated contents as the
response to the environmental stimuli like temperature [2],
pH [8], light [9], ultrasound [10,11], magnetic field [12,13],
and so on. These specific environment stimuli are used as
the driving force for triggered drug release based on the
interaction between the stimuli and liposomes. Among the
aforementioned stimuli, magnetic-triggered system has
become one of the most potential strategies as the release
and targeting stimuli.is is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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particles (MNP) has aroused great interest in magnetic-
based releasing system in biomedical applications due to
their physical properties and biocompatible nature [14,15].
MNP for biomedical applications should be hydrophilic
and stable in water [16]. Aqueous colloidal dispersions of
MNP hold great potential for use in a variety of novel and
existing bioprocesses because of the compatibility of the
aqueous medium with biosystem [17,18]. A number of
surfactants or compounds have been reported as a stabi-
lizing agent of MNP. Among of them, citric acid (CA) is
frequently used to obtain an aqueous stable dispersion of
MNP [17,19-23]. Targeting drug delivery system can be
divided into two general categories: passive and active.
MNP provided the main advantages of both types of
targeting: as with passive targeting, modification of the
nanoparticle surface is not necessary, and like active
targeting, they can be directed to the site of interest [2].
This is due to the fact that MNP respond strongly to the
magnetic fields, and magnetic fields can penetrate human
tissue without impediment [24]. Furthermore, MNP accu-
mulated in a tumor can act as hyperthermia-inducing
agents, using the exothermic properties derived from hys-
teresis and/or Néel relaxation losses by application of
high-frequency magnetic field (HFMF) to raise the local
temperature around the cells [16,23,25]. Moreover, MNP
have been used as a part of integrating system with
liposomes termed as magnetic liposomes or magnetolipo-
somes [24-26].
HFMF is one of the most promising external stimulus
because it is less invasive than other methods and has a
high permeability in relation to the human body and can
be operated remotely. HFMF can depress the drug-drug
carrier interaction and accelerate diffusion [16]. Drug re-
lease rate is significantly enhanced in the presence of a
magnetic field because of the pulsatile mechanical de-
formation that generates compressive and tensile stresses.
Moreover, HFMF-triggered drug delivery system utilized
the collapse or the volume transition of drug carriers then
induce the drug release [27]. Previous study confirmed
that the combination of dual-functional (magnetic and
thermal) drug carriers upon the exposure to the HFMF
upon a short time could lead to heating effect and a rapid
release, hence could enhance the wide application for
biomedical applications [28].
In the present work, we reported the preparation and
evaluation of doxorubicin-loaded magnetic liposomes for
colorectal cancer cells (CT-26 cells) treatment. The result-
ant of doxorubicin-loaded magnetic liposomes were sub-
ject to characterization including transmission electron
microscopy (TEM), dynamic light scattering (DLS), X-ray
diffraction (XRD), zeta potential, Fourier transform infra-
red (FTIR) spectrophotometer, and fluorescence micros-
copy. Biocompatibility was evaluated with mammaliancells (L-929 fibroblast). Further, the efficacy of this drug
carrier against CT-26 cells with HFMF exposure was
conducted to define the efficacy of this treatment.
Methods
Synthesis of aqueous stable CAMNP
The coprecipitation method was used for the synthesis of
citric acid-coated magnetic nanoparticles as the method
described previously with minor modification [14,18,19].
Briefly, FeCl3.6H2O and FeCl2.4H2O (molar ratio of 2:1)
were mixed using double-distilled water and stirred at
1,000 rpm in a three-necked flask. The temperature of the
solution was increased to 80°C in N2 atmosphere and kept
for 30 min. Further, 20 mL of ammonia solution was
added while mixing. The mixture was allowed to complete
the magnetite formation for 30 min; afterwards, 0.5 g/mL
CA was added, and the reaction temperature was in-
creased to 90°C and kept for 1 h with continuous stirring.
The black precipitates were harvested by cooling the
reaction mixture to the room temperature, and then
the particles were allowed to settle down with the help of
a magnet. Further, these magnetic nanoparticles were
washed carefully using double-distilled water. The products
were dried under vacuum at room temperature and termed
as citric acid-coated magnetic nanoparticles (CAMNP).
Preparation of liposomes and DOX-loaded magnetic
liposomes
Liposomes composed of fully hydrogenated soy phosphat-
idylcholine (HSPC)/1,2-distearoyl-sn-glycero-3-phosphoetha-
nolamine (DSPE)/cholesterol at mole ratios of 12.5:1:8.25
were prepared via conventional thin film hydration tech-
nique as method described previously with minor modifi-
cation [29,30]. Briefly HSPC, DSPE, and cholesterol were
dissolved in chloroform and ethanol (3:1 v/v). The mixture
was transferred into a 300-mL round bottom flask and
placed to rotary evaporation system (N-1200 series, Eyela®,
Tokyo Rikakikai Co., Ltd., Tokyo, Japan) for the elimin-
ation of any traces and residual of organic solvents.
Further, a thin dry lipid film would form on the wall of the
round bottom flask. This thin dry lipid film was kept in
rotary evaporation system for 6 h to ensure complete
removal of organic solvents. Hydration process of the dry
lipid film was accomplished by adding the phosphate
buffer solution (PBS) of pH 7.4, which resulted in lipo-
some suspension. In addition, CAMNP and doxorubicin
(DOX)/CAMNP were introduced in the hydration process
to obtain magnetic liposomes and DOX-loaded magnetic
liposomes, respectively. This suspension was subjected to a
bath-type sonicator (Ultrasonic Cleaner, Kudos, Shanghai,
China) for harvesting the liposomes. Afterward, the lipo-
somes were homogenized using ultrasonicator (Probe-type
sonicator, VCX 750, Vibra-Cell™, SONICS®, Sonics and
Materials, Inc., Newton, CT, USA) at 24 W for 10 min.
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15 min, which precipitated unincorporated magnetic
particles at the bottom of the tube and retained the drug-
containing magnetic liposomes in the supernatant [13].
Further, the suspension was dialyzed to remove unincor-
porated DOX [31]. Then, the suspension was extruded
through a 0.22-μm filter for sterilization and to reduce the
size. Furthermore, the resulting suspensions of liposomes
were then preserved at 4°C prior to characterizations.
Characterization
Particle size was measured using a DLS spectrophotometry
(Horiba Instrument, Horiba, Kyoto, Japan) with helium-
neon laser with wavelength of 633 nm, scattering angle of
90°, and refractive index of 1.33 at 25°C. The zeta potential
was determined through electrophoretic mobility meas-
urement (Horiba Instrument) with the following specifica-
tions: a dispersion medium viscosity of 0.894 mPa.s, a
refractive index of 1.33, and temperature of 25°C. The
structure and morphology of liposomes and doxorubicin
liposomes were examined using transmission electron
microscope (TEM-7650, Hitachi, Chiyoda-ku, Japan) at an
acceleration voltage of 75 kV. Phosphotungstic acid (PTA)
1%w/v was used as the staining agent. For CAMNP
and DOX-loaded magnetic liposomes, TEM was con-
ducted without using PTA. XRD was conducted using a
D2 Phaser BRUKER X-ray powder diffractometer (Bruker
AXS, Inc., Madison, WI, USA) to evaluate the crystallo-
graphic characteristics by scanning dried powder in the 2θ
range of 20° to 70° with Cu Kα-1 (1.5406 Å) radiation. The
infrared spectra were recorded using a FTIR-460 PLUS
(Jasco Co. Ltd., Tokyo, Japan) to determine the major
characteristic functional groups. Briefly, the sample was
mixed with KBr pellet, and the mixtures were pressed
into a pellet form prior to characterization. The incorpor-
ation of DOX into the drug carrier was visualized using
fluorescence microscope (Olympus, Shinjuku-ku, Japan)
equipped with a × 40 objective. Fluorescence images were
obtained with a fluorescence microscope (Olympus) at
wavelengths of 490 (excitation) and 590 nm (emission).
The amount of DOX encapsulated into the liposomes or
DOX-loaded magnetic liposomes was determined by a
fluorescence spectrophotometer at wavelength of 490 nm
for excitation and 590 nm for emission, after lysis of
liposomes with a sufficient amount of acetonitrile [13].
The encapsulation efficiency (EE) was calculated by the
amount of drug encapsulated/initial drug loading × 100%.
Hyperthermia experiment
Hyperthermia experiment was performed as the method
reported previously with minor modification [32]. Adia-
batic condition is assumed, where the initial temperature
of the sample must be equal to the temperature of the
surrounding medium [33]. Therefore, the temperature ofthe surrounding medium was kept constant using a
heated chamber at 37°C then the initial temperature was
37°C for all of the measurements. Briefly, CAMNP and
or DOX-loaded magnetic liposomes suspension were
subjected to the center of copper coil in the HFMF ap-
paratus for 10 min. The change of the temperature was
recorded every 2 min by an alcohol thermometer. Each
experiment was performed three times.
In vitro drug release test
In vitro drug release test was conducted to evaluate the
release behavior of DOX from drug carriers during the
exposure of HFMF. Before conducting drug release test,
the system was first purified using centrifugation in order
to remove the unincorporated magnetic nanoparticles
[25]. Briefly, doxorubicin liposomes and DOX-loaded
magnetic liposomes were placed into glass tube which
contained the release solution (pH 4) and placed under
HFMF for 10 min. About 1 mL of drug was taken from
the test tube during the test for 2 min first and continued
2 min until 10 min during HFMF exposure. The quantity
of DOX was quantified using UV-visible spectrophotom-
eter at wavelength of 480 nm.
The drug release percent was evaluated by applying
Equation 1:
Cumulative release %ð Þ ¼ Rt=D  100% ð1Þ
where D and Rt represent the initial amount of drug
loaded and the cumulative amount of drug released at
time t, respectively.
Cell culture
Mouse fibroblasts (L-929 cells) were obtained from ATCC
CRL-1503TM. Dulbecco's modified Eagle's medium
high glucose (DMEM), trypsin, dimethylsulfoxide (DMSO),
trypan blue, and 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) powder were purchased from
Sigma Aldrich, St. Louis, MO, USA. Fetal bovine serum
(FBS) was purchased from BD Biosciences, San Jose, CA,
USA. Fibroblasts cells (L929) were cultured using DMEM
containing 10 vol.% FBS and 1 vol.% antibiotic antimycotic
solution. The cultures were incubated under saturated
humid conditions at 37°C with 5% CO2. The medium was
changed every day until reaching approximately 70% to
80% confluency. Mouse colon carcinoma cell line (CT-26)
was obtained from Bioresource Collection and Research
Centre (BCRC, Hsinchu, Taiwan). The controlled cell
(CT-26-Ctrl) was cotransfected with pLKO-AS3W-neo
plasmid and packaging plasmid and infected with virus in
order to grow up the tumor cell. After antibiotic selection
for 2 weeks, the CT-26-Ctrl was obtained. CT-26 cells
were cultured using DMEM containing 10 vol.% FBS and
1 vol.% antibiotic antimycotic solution. The cultures were
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5% CO2. The medium was changed every day until reach-
ing approximately 70% to 80% confluency.
MTT cytotoxicity analysis
Cell growth and cytotoxicity were determined using MTT
assay. In 24-well plates, 5,000 cells were cultured in each
well. These plates were divided into several groups and in-
cubated under saturated humid conditions at 37°C and 5%
CO2. After 24 h of incubation, the medium was replen-
ished. Among these plates, some plates were added with
sample-containing medium. In addition, the negative con-
trol contained only medium, while the positive control was
medium containing 5% DMSO. After culturing for 1, 3,
and 5 days, 0.1 mL of MTT solution and 0.9 mL of
medium were added to each well. After incubating for an-
other 3 h at 37°C, the medium was withdrawn and re-
placed with 500 μL DMSO and allowed to stand about
15 min for complete reaction. Furthermore, the plates were
shaken, and the readings were taken at 570 nm using an
ELISA reader (Sunrise, Tecan, Männedorf, Switzerland).
Proliferation on the first, third and fifth days was calculated
as follows [29]:
Proliferation %ð Þ ¼ Ac=A0  100% ð2Þ
where Ac is the absorbance of each system in each day
and A0 is the absorbance of the control on day 0.
In vitro evaluation of chemotherapy and hyperthermia
studies
In vitro evaluation of chemotherapy and hyperthermia was
conducted using drug carriers against CT-26 cells with
HFMF exposure. Briefly, CT-26 cells were incubated with
liposomes, doxorubicin liposomes, magnetic liposomes, or
DOX-loaded magnetic liposomes (DOX concentration:
1 μM) in a 15-mL polypropylene tube which is positioned
in the center of a copper coil in the HFMF system. The
cells were exposed to the HFMF for 10 min. After the
treatment, the cells were washed and seeded in a 96-well
plate at a density of 10,000 cells per well and were incu-
bated for another 24, 48, and 72 h. Furthermore, the MTT
assay was conducted as aforementioned method and was
taken at 570 nm using an ELISA reader (Sunrise, Tecan).
Results and discussion
Figure 1a1 shows the TEM image of CAMNP which
showed a spherical morphology of nanoparticles in the
range of 10 nm. Under high-resolution TEM (insert
Figure 1a2), CAMNP exhibited a crystalline structure.
Figure 1b shows a selected area diffraction pattern of the
CAMNP which showed six planes, namely, [220], [311],
[400], [422], [511], and [440], indicating the presence of
Fe3O4 nanoparticles. The citric acid coating might be formas a thin layer coating on the surface of MNP hence did
not change any structure and crystallinity properties of
magnetite nanoparticles. Furthermore, EDS analysis shows
the prepared CAMNP contained the elements of Fe and O
(Figure 1c). Figure 1d1 shows the CAMNP could disperse
properly in the aqueous solution and exhibit the inter-
action with the magnetic exposure (Figure 1d2). This char-
acteristic was generated due to the presence of carboxylic
moiety on the surface of MNP (Figure 1e1). Because of
their amphiphatic nature of liposomes, doxorubicin (DOX)
and CAMNP are expected to be readily incorporated into
hydrophilic moiety of liposomes (Figure 1e2).
The morphology of liposomes, doxorubicin lipo-
somes, and DOX-loaded magnetic liposomes was ob-
served in TEM images with the particle size of 100, 117,
and 130 nm, respectively (Figure 2a1,a3). Figure 2b1,b2
shows the fluorescence images of doxorubicin liposomes
and DOX-loaded magnetic liposomes, respectively. The
DOX itself carries the fluorescence properties [11] that
could be explored to detect the presence of DOX in the li-
posomes. Liposomes without DOX did not present any
fluorescence signal (not shown); meanwhile doxorubicin
liposomes and DOX-loaded magnetic liposomes present
the red signal which was generated from DOX. Moreover,
this revealed the incorporation of DOX in both of doxo-
rubicin liposomes and DOX-loaded magnetic liposomes.
The synthesized pristine MNP and CAMNP showed
X-ray diffraction pattern of multiple peaks within the 2θ
range of 20° to 70° (Figure 3a). Six diffractions peaks at
2θ = 30.1°, 35.6°, 43.3°, 53.5°, 57.2°, and 62.9° were the
characteristic peaks of the crystal plane which was ap-
propriated with the standard diffraction spectrum
(JCPDS: 85-1436) indicating the formation of magnetite
nanoparticles [28]. The diffraction data were also used
to measure the primary particle size according to Scherrer
analysis for diffraction peak widths of (311) peak. The
crystallite size was determined from the X-ray line broad-
ening using Scherrer's formula D = 0.9λ/β cos θ, where D
is the average of crystallite size, λ is the X-ray wavelength
used, β is the angular line width of half maximum inten-
sity, and θ is the Bragg's angle in degrees. Based on this
method, the primary crystallite size of magnetite nanopar-
ticle was estimated about 9 nm. FTIR spectrum (Figure 3b)
was conducted to observe the major functional groups
and molecular interaction between the components in the
drug carriers. For the MNP, the characteristic absorption
peaks at 578 cm−1 [34]. The characteristic peaks of CA
were shifted due to the interaction between CA and MNP
nanoparticles [14,17,33]. The peaks at 3,445 cm−1 (hy-
droxyl group), 1,727 cm−1 (symmetric vibrational of C =O
from –COOH group), 1,387 cm−1 (asymmetric C-O
stretching from -COOH group) were shifted to 3,328,
1,643, and 1,257 cm−1, respectively. This observation
might be attributed to the binding of CA onto the surface
Figure 1 TEM images, diffraction patterns, EDS, photographs, and diagram. TEM image of citric acid-coated magnetic nanoparticles
(CAMNP) (a1) and high-resolution TEM image showing the crystalline condition of iron oxide in CAMNP (a2). Diffraction pattern (b) and EDS (c)
of CAMNP. Photographs of CAMNP in the aqueous system, before (d1) and after (d2) the exposure of magnet. Diagram showing the proposed
synthesis of surface modification MNP using CA (e1) and the preparation of DOX-loaded magnetic liposomes and its interaction with HFMF (e2).
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The peak around 2,901 cm−1 is corresponding to the C-H
stretching peaks from CH2 groups in CA molecules [14].
Furthermore, these results confirmed the presence of
CA on the surface of MNP. In addition, the peakscorresponding to phospholipid were observed at 1,240
and 1,656 cm−1 for peaks of phospholipids and C = O
stretching, respectively [25]. These provide the infor-
mation about the liposomes layer which encapsulated
magnetic nanoparticles.
Figure 2 TEM images and fluorescence microscope images. TEM images of liposomes (a1), doxorubicin liposomes (a2), DOX-loaded magnetic
liposomes (a3), and DOX-loaded magnetic liposomes after HFMF treatment (a4). Fluorescence microscope images of doxorubicin liposomes (b1) and
DOX-loaded magnetic liposomes (b2).
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tial values against pH values. High zeta potential value of
CAMNP provides electrostatic and steric stabilization in
the wide range of pH from the lower pH value (pH ap-
proximately 4) until physiological pH (pH approximately
7.4) which will increase the broad application of these
nanoparticles for tumor or cancer treatment (lower pH),
but on the other side still stable in the physiological pH
condition. This result is in accordance with the character-
istics previously reported [35,36]. Figure 4b (circle) shows
the zeta potential value of each components in the drug
carriers. Zeta potential value of pristine Fe3O4 is −40 mV.
This result might be due to a number of hydroxyl groups
(Fe-OH) [16]. Surface modification of MNP using CA in-
creased the zeta potential value to −50 mV at pH 7.4.
These might be due to CA adsorbed on the surface of the
MNP by coordinating via one or two of the carboxylate
functionalities, depending on steric necessity and thecurvature of the surface. This leaves at least one carboxylic
acid group exposed to the solvent, and this group should
be responsible for making the surface charged and hydro-
philic [17]. DLS revealed that the particle size of lipo-
somes, doxorubicin liposomes, magnetic liposomes, and
DOX-loaded magnetic liposomes was 107, 130, 149, and
154 nm, respectively (Figure 4b, square sign). This appro-
priate size was necessary for a drug delivery system
to escape from reticuloendothelial system (RES) system
[13,14,37]. This is in accordance with the characteristic
previously reported [38,39]. Incorporation of CAMNP into
the liposomes changes zeta potential values into −24 mV.
These further prove the encapsulation of CAMNP by
liposomes. In addition, negative surface charges of drug
carriers may enhance the particle circulating time with
avoiding of the opsonization process, the process related
to the promoting of particle recognition by the cells due
to the interaction between the protein entity-adsorbed
Figure 3 XRD and FTIR spectra. XRD (a) of pristine MNP and CAMNP. FTIR spectra (b) of MNP, CA, CAMNP, and DOX-loaded
magnetic liposomes.
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monocytes and various subsets of tissue macrophages [37].
Figure 5a shows the results of inductive heating ability
of various formulations of CAMNP and DOX-loaded
magnetic liposomes. Inductive heating is thermal energy
induced from the hysteresis loss of ferrites and dependent
on the type of remagnetization process in the HFMF [28].
Control sample (double-distilled water) did not heat
up significantly under the exposure of HFMF, and the
temperature remained around 37°C. Meanwhile, DOX-
loaded magnetic liposomes could reach the hyperthermia
temperature (approximately 42°C) after the exposure of
HFMF around 10 min. These results confirmed that
the temperature increased in the DOX-loaded magneticliposomes closely related to the incorporation of mag-
netic nanoparticles (CAMNP) in the liposome com-
partment. Based on the fluorescence spectrophotometer,
drug loading of DOX was 221 and 155 ng/μl in the pris-
tine liposomes and magnetic liposomes, respectively. The
encapsulation efficiency (EE) of DOX was 22.1% for the
pristine liposomes and 15.5% for magnetic liposomes. In
vitro drug release test was conducted in order to investi-
gate the release behavior of DOX from the drug carriers
As shown in Figure 5b, the HFMF exposure generate the
bursting-like release profile of DOX in DOX-loaded mag-
netic liposomes, about more than 80% release of DOX;
meanwhile, there is no significant burst release shown by
DOX encapsulated in the liposomes which is just 40%
Figure 4 Particle size and zeta potential measurements. Zeta potential of CAMNP against pH values (a). Particle size and zeta potential of
liposomes (Lip), doxorubicin liposomes (Lip-Dox), magnetic liposomes (Mag-Lip), and DOX-loaded magnetic liposomes (Dox@Mag-Lip) (b).
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incorporation of CAMNP in the magnetic liposomes
which further generate heat and initiate DOX release
simultaneously. The heating induced by the exposure
of HFMF might affect the structural disorder (collapse) of
lipids which further generates the drug release, as shown
in Figure 2a4.
MTT assay was conducted to determine the cellular
cytotoxicity of liposomes and magnetic liposomes using
L-929 cells, as the mammalian cell model. Figure 6a
shows the L-929 cells treated with cytotoxic compound
(DMSO) as a positive control which resulted in the
death of the cells. Moreover, as shown in Figure 6b,c,d,the morphology of the treated cells were similar with the
cells in the negative group control (treated only with
medium). The morphological observation using optical
microscope confirmed that no toxicity effects were found
compared to the negative control, indicating that the drug
carrier component exhibited less influence on the growing
of the cells as the cells remained viable and continued to
proliferate. Figure 6e shows the cell proliferation based on
the MTT assay. Based on the cell proliferation of L-929
fibroblasts cells, we found that the cells grow during the
day of incubation. Liposomes and magnetic liposomes
exhibited a good proliferation probably due to the biocom-
patibility of the liposome system with the cell compartment.
Figure 5 Heating ability and cumulative release. Heating ability of CAMNP and DOX-loaded magnetic liposomes (a). Cumulative release (%)
of DOX from doxorubicin liposomes and DOX-loaded magnetic liposomes with HFMF exposure (b).
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modified magnetic nanoparticles into the liposome com-
partment totally resolved the problems related to the
physical behavior of charged surface nanoparticles which
tend to react with the serum proteins which might be
present on the cell culture medium [40]. Eventually, these
results confirmed that drug carriers exhibited no cyto-
toxicity against L-929 cells, suggesting good biocompati-
bility. This is in accordance with similar characteristic
previously reported [41,42].
Figure 7a shows the effect of the in vitro hyperthermia
treatment with various samples (contained 1 μM of DOX)
against CT-26 cells, and Figure 7b shows the optical
microscope image of CT-26 cancer cells after treated withvarious formulations. After HFMF treatment, blank lipo-
somes exhibited no effect to the apoptosis of cancer cells.
Liposomes contained CAMNP exhibited a cell cytotoxicity
effect which resulted in 15% cancer cell death (after 1 day
of incubation). These killing effects might be because of
the hyperthermia effects through the absorption of heat
by CAMNP. On the other hand, the liposomes that con-
tain DOX also exhibited the apoptosis effect to the cancer
cells after treatment using HFMF. This formulation killed
38% (after 1 day of incubation) of cancer cells during the
treatment of HFMF. These phenomena might be because
of the structure disruption of the liposomes when HFMF
was applied to them and generate the releasing of DOX
into the cancer site. These results directly proved the
Figure 6 MTT assays and cytotoxicity studies against L-929 cells. Optical microscopy images of L-929 after incubation with positive control
(a1-a5), negative control (b1-b5), liposomes (c1-c5), and magnetic liposomes (d1-d5) during 1, 3, and 5 days of incubation. Cell proliferation (%)
of L-929 cells during 1, 3, and 5 days of incubation (e).
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Figure 7 MTT assays and cytotoxicity studies against CT-26 cells. After HFMF exposure with liposomes, magnetic liposomes, doxorubicin
liposomes, and DOX-loaded magnetic liposomes (a). Optical microscope images of CT-26 cells after treated with liposomes (b1), magnetic
liposomes (b2), doxorubicin liposomes, (b3), and DOX-loaded magnetic liposomes (b4). Proposed mechanism of HFMF treatments in
combination with DOX-loaded magnetic liposomes (c).
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DOX is known to interact with DNA by intercalation and
inhibition of DNA biosynthesis [43]. Interestingly, the
formulation of DOX-loaded magnetic liposomes exhibited
the highest degree of cytotoxicity to the CT-26 cancer
cells which further influence cell apoptosis (56% of cancer
cells were killed, after 1 day of incubation). In this case,
CAMNP will absorb and generate heat when HFMF is
applied to them. This heating absorption is useful for
driving force for DOX release and also provide the heating
(thermotherapy) effect to the cancer cells [16]. DOX en-
capsulated in magnetic liposomal system are expected to
be readily delivered to the tumor cells due to the nonphys-
ical interaction between HFMF and CAMNP. Hence, the
combination of the tri-components with HFMF treatment
will generate multifunctional effects to kill the cancer cells
(Figure 7c). In biological perspective, hyperthermia might
kill the cells by irreversibly damaging different cellular
structures like cell membrane and cytoskeleton and caus-
ing damage to enzyme complexes required for DNA syn-
thesis and repair. Hyperthermia irreversibly damages the
actin and tubulin structures of cells which would lead to
apoptosis [14]. Hyperthermia also could increase DOX ab-
sorption due to the addition of blood flow in the tumor
region and decrease the tumor vessel regeneration for the
reduction of synthesis and secretion of VEGF [44]. Even-
tually, the integrating therapy system of hyperthermia
could increase the cytotoxic effects against cancer cells.
These results suggest the promising application of this
system for cancer treatment.
Conclusions
Formulation of liposomes containing doxorubicin and
magnetic nanoparticles has been developed as a part in
the integrating treatment of chemotherapy and hyper-
thermia with the introduction of high-frequency magnetic
field system. Cytotoxicity screening of blank drug carriers
against mammalian cells, L-929 fibroblast cells, showed
that these drug carriers exhibited no cytotoxicity against
cellular system which further emphasized these drug car-
riers as a potential candidate for biocompatible materials.
However, the combination between DOX and magnetic li-
posomes (drug concentration 1 μM) and high-frequency
magnetic field treatment synergistically would increase
the cytotoxicity effects to kill colorectal cancer cells. Even-
tually, these results confirmed the potential applica-
tion of this drug carrier for cancer treatment throughcombination between chemotherapy (drug-controlled
release) and hyperthermia (inductive heating).
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